Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Hellstrom-Lindberg, Eva  [Clear All Filters]
2024
Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Kittang AOlsnes, Werlenius O, et al. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2024:JCO2301159.
2023
Hakkarainen M, Kaaja I, Douglas SPM, Vulliamy TJ, Dokal I, Soulier J, Larcher L, de Latour RPeffault, Leblanc TM, de Fontbrune FSicre, et al. The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia. Blood. 2023.
Moura PL, Blanco TMortera, Hofman IJ, Todisco G, Kretzschmar WW, Björklund A-C, Creignou M, Hagemann-Jensen M, Ziegenhain C, Granados DCabrerizo, et al. Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts. Cancer Res. 2023.
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Todisco G, Creignou M, Bernard E, Björklund A-C, Moura PLuis, Tesi B, Blanco TMortera, Sander B, Jansson M, Walldin G, et al. Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts. Clin Cancer Res. 2023.
Cieśla M, Ngoc PCao Thi, Muthukumar S, Todisco G, Madej M, Fritz H, Dimitriou M, Incarnato D, Hellstrom-Lindberg E, Bellodi C. mA-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Mol Cell. 2023.
2022
Todisco G, Moura PL, Hellstrom-Lindberg E. Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?. Semin Hematol. 2022;59(3):150-155.
Hofman IJuliana, Mortera-Blanco T, Moura PLuis, Vestlund J, Larsson SVenckute, Elvarsdottir EMaria, Walldin G, Tobiasson M, Sander B, Dimitriou M, et al. The extent of residual WT hematopoietic stem and progenitor cells is associated with the degree of anemia in SF3B1-mutated MDS-RS patients. Blood Adv. 2022.
Asimomitis G, Deslauriers AG, Kotini AG, Bernard E, Esposito D, Olszewska M, Spyrou N, Ossa JEsteban Ar, Mortera-Blanco T, Koche RPatrick, et al. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Adv. 2022.
2021
Wedge E, Hansen JWerner, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MSkov, Nilsson L, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021.
2020
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermak J, Dinmohamed AG, Eeltink C, Eggmann S, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
2013
Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Cañizo C, Porta MGDella, Fenaux P, Gattermann N, Germing U, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013.
Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Porta MGDella, Jadersten M, Verma A, et al. Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. J Clin Oncol. 2013.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.